Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains

AIDS Research and Human Retroviruses

Volumn 23, Issue 12, 2007, Pages 1593-1598

  Eshleman, Susan H ^a,e   Hudelson, Sarah E ^a   Bruce, Robert ^b   Lee, Travis ^c   Owens, Michelle R ^b   Hackett Jr , John ^d   Swanson, Priscilla ^d   Devare, Sushil G ^d   Marlowe, Natalia ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CELERA   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41;

ARGENTINA; ARTICLE; BLOOD DONOR; BRAZIL; CAMEROON; ENVELOPE GENE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA; STRUCTURAL GENE; THAILAND; UGANDA; VIRUS GENE; VIRUS RECOMBINANT; VIRUS STRAIN;

BASE SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT;

EID: 37549002527     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0130     Document Type: Article

References (14)

1. Greenberg ML and Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-340.
2. Briz V, Poveda E, and Soriano V: HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother 2006;57:619-627.
3. Holguin A, Faudon JL, Labernardiere JL, and Soriano V: Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol 2007;38:176-180.
4. Cilliers T, Patience T, Pillay C, Papathanasopoulos M, and Morris L: Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004;20:477-482.
5. Swanson P, Devare SG, and Hackett J Jr: Molecular characterization of 39 HIV isolates representing group M (subtypes A-G) and group O: Sequence analysis of gag p24, pol integrase, and env gp41. AIDS Res Hum Retroviruses 2003;19:625-629.
6. Stanford HIV Resistance Database: Antiretroviral drug summaries: Enfuvirtide (ENF, Fuzion). http://hivdb.stanford.edu. Accessed April 13, 2007.
7. Los Alamos HIV Drug Resistance Database. http://resdb.lanl.gov/Resist_DB. Accessed April 13, 2007.
8. Xu L, Pozniak A, Wildfire A, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-1119.
9. Aquaro S, D'Arrigo R, Svicher V, et al.: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58:714-722.
10. Lu J, Deeks SG, Hoh R, et al.: Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60-64.
11. Melby T, Sista P, DeMasi R, et al.: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22:375-385.
12. Carmona R, Perez-Alvarez L, Munoz M, et al.: Natural resistance- associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 2005;32:248-253.
13. Cabrera C, Marfil S, Garcia E, et al.: Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006;20:2075-2080.
14. Aghokeng AF, Ewane L, Awazi B, et al.: Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa. AIDS Res Hum Retroviruses 2005;21:430-433.